You are here

  • Home
  • Archive
  • Volume 71, Issue 1
  • First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

Citation Tools

Article menu
Inflammatory bowel disease
Original research
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Jongsma MME, Aardoom MA, Cozijnsen MA, et al
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
Gut 2022;71:34-42.